High-grade serous ovarian carcinoma is an aggressive and heterogeneous disease with a poor prognosis, and it is often diagnosed at an advanced stage. Genetic information on DNA repair is increasingly used in diagnosis, risk assessment, and treatment selection and will ostensibly translate to an overall survival benefit—at least for certain subgroups of patients. In this commentary, we outline the promise and challenges of precision oncology and discuss how the prospects depend not only on genomic data but also on deep-tissue immune profiling. The technological breakthroughs in antibody-based therapies have paved the way for the introduction of new therapeutics.
- Katrin Kleinmanns
- Line Bjørge
